HEMOPHILIA CARE IN THE NEW MILLENNIUM

Edited by

Dougald M. Monroe
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Ulla Hedner
Novo Nordisk A/S, Målov, Denmark and
University of Lund, Lund, Sweden

Maureane R. Hoffman
Duke University and Durham VA Medical Centers
Durham, North Carolina

Claude Negrier
Hôpital Edouard Herriot
Lyon, France

Geoffrey F. Savidge
Guys' and St. Thomas's Trust
London, United Kingdom

and

Gilbert C. White II
University of North Carolina School of Medicine
Chapel Hill, North Carolina

KLUIWER ACADEMIC / PLENUM PUBLISHERS
New York, Boston, Dordrecht, London, Moscow
Contents

I. Infectious Disease Risk

1. The Transfusion-Transmitted Viruses in Blood Transfusion .................. 1
   Naomi L.C. Luban and Rima F. Jubran

II. Unexplained Aspects of Hemophilia and Hemostasis

2. Are Patients with Glanzmann Thrombasthenia and the Bernard-
   Soulier Syndrome Protected Against Atherosclerosis? .................. 13
   Alan T. Nurden, Paquita Nurden and James N. George

3. Factor V: Dr. Jeckyll and Mr. Hyde .................................... 31
   Michael Kalafatis and Kenneth G. Mann

III. Novel Approaches to Therapy

4. Gene Therapy for Hemophilia B: AAV-Mediated Transfer of the
   Gene for Coagulation Factor IX to Human Muscle .................. 45
   Peter J. Larson and Katherine A. High

5. Use of Prophylaxis to Prevent Complications of Hemophilia .......... 59
   Pier M. Mannucci, L. Mendolicchio and A. Gringeri

6. Factor VIII Inhibitors .................................................... 65
   Pete Lollar, John F. Healey, Rachel T. Barrow, Ernest T. Parker

7. Use of High Dose Factor VIIa in Hemophilia Patients .................. 75
   Ulla Hedner

IV. Inhibitor Development in Hemophilia Patients

8. The Incidence of Inhibitors in Hemophilia A and the Induction of
   Immune Tolerance .......................................................... 89
   Ernest Briët and Marjolein Peters
   Marc G. Jacquemin, Beatrijs Vanzieleghem and
   Jean-Marie R. Saint-Remy

10. Mechanisms of Unresponsiveness: T- and B-Cell Mediated
    Mechanisms of Anergy .......................................................... 109
    Roberta Greenwood and Jeffrey Frelinger

11. CD4+ T Cells Specific for Factor VIII as a Target for Specific
    Suppression of Inhibitor Production ........................................ 119
    Mark T. Reding, Huiyun Wu, Mark Krampf, David K.
    Okita, Brenda M. Diethelm-Okita, Nigel S. Key and
    Bianca M. Conti-Fine

12. CD40L Pathway Blockade as an Approach to Immuno-
    therapy .................................................................................. 135
    Linda C. Burkly

Abstracts ..................................................................................... 153

Contributors .................................................................................. 171

Index ............................................................................................ 175